Oncology News | pharmaphorum

News

Brukinsa data raises chemo-free hope for mantle cell lymphom...

Patients with newly diagnosed mantle cell lymphoma could avoid chemotherapy with a regimen based on BeOne's Brukinsa, according to the MANGROVE trial.

News

Ipsen charts $1.75bn course for Kartos acquisition

Ipsen has agreed to buy cancer biotech Kartos Therapeutics for $450m upfront, adding a late-stage drug in the challenging MDM2 inhibitor class.

News

Moderna shows in vivo CAR-T hand in R&D update

At its latest R&D update, Moderna revealed a move into the pioneering in vivo CAR-T category, adding another treatment class to its R&D capabilities.

News

Ibrance cleared in US for 'double-positive' breast cancer

Ibrance has become the first CDK4/6 inhibitor to be approved for a challenging subtype of breast cancer that is often resistant to current treatment.

News

NICE delivers more good news for cervical cancer patients

Hundreds of women with locally advanced cervical cancer are to be offered MSD's Keytruda on the NHS in England, thanks to new NICE guidance.

News

NICE says Libtayo can be used for advanced cervical cancer

New NICE guidance means that around 90 UK women with cervical cancer should be eligible for treatment with Regeneron's Libtayo each year.

Brukinsa data raises chemo-free hope for mantle cell lymphom...

Ipsen charts $1.75bn course for Kartos acquisition

Moderna shows in vivo CAR-T hand in R&D update

Ibrance cleared in US for 'double-positive' breast cancer

NICE delivers more good news for cervical cancer patients

NICE says Libtayo can be used for advanced cervical cancer

ASCO 2026: All about DNA damage response, with Luke Piggot

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks